- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06107504
Prevention of Post-sphincterotomy Bleeding
Prevention of Post-sphincterotomy Bleeding by Endoscopic Tranexamic Acid and Sucralfate Administration: A Randomized Controlled Trial
Background and Aim: Endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy (EST) are standard treatments for choledocholithiasis. However, 10% of post-EST bleeding was reported. Currently, there are no effective methods or medications for the prevention of post-EST bleeding. This study aimed to investigate whether the local administration of TXA and sucralfate can reduce the post-EST bleeding event.
Methods: This is a randomized clinical trial. Patients with choledocholithiasis scheduled for ERCP with EST at National Cheng Kung University Hospital were enrolled. The study will recruit 60 patients. After randomization, 30 patients will be classified into the intervention group and 30 into the control group. The participants will receive standard ERCP and EST for common bile duct stone removal. If immediate polypectomy bleeding occurs, the investigators will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. After then, the investigators will spray 2g of sucralfate powder and 1g of tranexamic acid through duodenoscopy precisely on the post-EST wound in the intervention group. All enrolled patients will be monitored for delayed bleeding for 14 days after the ERCP.
Study Overview
Detailed Description
Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic procedure combining endoscopy and fluoroscopy to diagnose and treat diseases of the pancreaticobiliary ductal system, including choledocholithiasis, biliary strictures, and cholangitis. ERCP is associated with a higher rate of complications than other endoscopic procedures, including post-ERCP pancreatitis (PEP), bleeding, perforation, and biliary tract infection. The incidence rate of ERCP-related complications has been reported at approximately 10 percent, with mortality rates ranging from 0.1 to 1.4 percent. Despite recent technological advancements and safety precautions, the ERCP procedure-related death rates have remained high.
Among all complications, delayed bleeding after sphincterotomy (EST) is a nightmare for both clinical physicians and endoscopists. Post-EST bleeding results in Tarry-bloody stool and anemia, increasing the mortality rate and hospital stay. While non-steroidal anti-inflammatory drugs (NSAIDs), pancreatic stents, and intravenous fluids can help prevent post-ERCP pancreatitis, there is no effective methodology or medication for bleeding prevention currently. Therefore, developing a prevention method for post-EST bleeding is urgent and important.
Tranexamic acid (TXA) is a well-known antifibrinolytic agent that inhibits fibrin degradation by binding to tissue plasminogen, thereby preventing blood clot lysis and reducing bleeding. A recent study evaluating the effect of topical tranexamic acid (TXA) powder on bleeding peptic ulcers demonstrated that the precise endoscopic administration of TXA powder can enhance the stop-bleeding effect.
Sucralfate, a complex of aluminum hydroxide and sucrose octa sulfate, can bind to the wound base. This protective barrier can prevent the wound from further environmental injury. Sucralfate has been widely used for wounds and ulcer treatment, e.g., skin wounds, oral ulcers, and peptic ulcers8. With the protective effect of the papilla mucosa, sucralfate can cover the EST wound and has the potential to avoid further environmental damage. In combination with TXA powder in stabilizing the clotting, we expect the post-EST bleeding event will reduce. Therefore, this study aimed to investigate whether the combination therapy of topical administration of TXA and sucralfate after EST can reduce the post-EST bleeding event.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hsueh-Chien Chiang, M.D.
- Phone Number: 9118 2353535
- Email: scion456scion@gmail.com
Study Contact Backup
- Name: Xi-Zhang Lin, M.D.
- Phone Number: 9118 2353535
- Email: linxz@mail.ncku.edu.tw
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥ 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction
Exclusion Criteria:
- Paitnets with no schedules for sphincterotomy
- Paitnets with unsuccessful CBD cannulation
- Patients with allergy to sucralfate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group.
After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation.
After then, we will spray 2g of sucralfate powder and 1g of tranexamic acid powder through a duodenoscope precisely on the EST wound in the intervention group.
|
2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
Other Names:
|
No Intervention: Control group
After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group.
After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incident rate of delayed post-ERCP bleeding during the study period
Time Frame: 14 days
|
The occurrence of delayed post-ERCP bleeding during the study period.
Delayed post-ERCP bleeding was defined as remarkable hematochezia or Tarry stool with endoscopic evidence of post-EST wound bleeding.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incident rate of post-EST wound bleeding requiring transarterial embolization or emergency surgery
Time Frame: 14 days
|
The incident rate of post-EST wound bleeding requiring transarterial embolization or emergency surgery.
|
14 days
|
The length of hospitalization
Time Frame: 14 days
|
The length of hospitalization
|
14 days
|
The mortality rate
Time Frame: 14 days
|
All-cause mortality after EST
|
14 days
|
The incident rate post-ERCP pancreatitis
Time Frame: 14 days
|
The incident rate post-ERCP pancreatitis after ERCP.
The definition is epigastric pain and elevated lipase.
|
14 days
|
Collaborators and Investigators
Publications and helpful links
General Publications
- ASGE Standards of Practice Committee; Buxbaum JL, Abbas Fehmi SM, Sultan S, Fishman DS, Qumseya BJ, Cortessis VK, Schilperoort H, Kysh L, Matsuoka L, Yachimski P, Agrawal D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee JK, Naveed M, Sawhney MS, Thosani N, Yang J, Wani SB. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019 Jun;89(6):1075-1105.e15. doi: 10.1016/j.gie.2018.10.001. Epub 2019 Apr 9.
- Masuelli L, Tumino G, Turriziani M, Modesti A, Bei R. Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action. Recent Pat Inflamm Allergy Drug Discov. 2010 Jan;4(1):25-36. doi: 10.2174/187221310789895649.
- Ala S, Saeedi M, Janbabai G, Ganji R, Azhdari E, Shiva A. Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial. Nutr Cancer. 2016;68(3):456-63. doi: 10.1080/01635581.2016.1153666. Epub 2016 Mar 23.
- Akshintala VS, Sperna Weiland CJ, Bhullar FA, Kamal A, Kanthasamy K, Kuo A, Tomasetti C, Gurakar M, Drenth JPH, Yadav D, Elmunzer BJ, Reddy DN, Goenka MK, Kochhar R, Kalloo AN, Khashab MA, van Geenen EJM, Singh VK. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 Sep;6(9):733-742. doi: 10.1016/S2468-1253(21)00170-9. Epub 2021 Jun 30.
- Fujita K, Yazumi S, Matsumoto H, Asada M, Nebiki H, Matsumoto K, Maruo T, Takenaka M, Tomoda T, Onoyama T, Kurita A, Ueki T, Katayama T, Kawamura T, Kawamoto H; Bilio-pancreatic Study Group of West Japan. Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post-endoscopic retrograde cholangiopancreatography pancreatitis. Dig Endosc. 2022 Sep;34(6):1198-1204. doi: 10.1111/den.14225. Epub 2022 Feb 4.
- Leung WK, But DY, Wong SY, Tong TS, Liu KS, Cheung KS, Tsang SH, Chok KS, Poon RT, Hung IF. Prevention of post-sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial. J Dig Dis. 2018 Jun;19(6):369-376. doi: 10.1111/1751-2980.12604. Epub 2018 May 24.
- Yu Z, He J, Cao R, Yang Z, Li B, Hong J, Chen Y, Zhu L. Proton pump inhibitor has no effect in the prevention of post-endoscopic sphincterotomy delayed bleeding: a prospective randomized controlled trial. Front Med (Lausanne). 2023 Jun 2;10:1179512. doi: 10.3389/fmed.2023.1179512. eCollection 2023.
- Chiang HC, Chen PJ, Yang EH, Hsieh MT, Shih IC, Cheng HC, Chang WL, Chen WY, Chiu HC, Kuo HY, Tsai WC, Lo YN, Yang KC, Chiang CM, Chen WC, Huang KK, Tseng HH, Chen CY, Lin XZ, Chuang CH. Precise application of topical tranexamic acid to enhance endoscopic hemostasis for peptic ulcer bleeding: a randomized controlled study (with video). Gastrointest Endosc. 2023 Nov;98(5):755-764. doi: 10.1016/j.gie.2023.06.013. Epub 2023 Jun 24.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-BR-112-038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-ERCP Bleeding
-
University of CalgaryRadboud University Medical Center; McGill University; University of Toronto; University... and other collaboratorsCompletedBleeding UGI (During or Post-ERCP)Canada
-
The University of Hong KongCompleted
-
University of MichiganUniversity of Kentucky; Case Western Reserve University; Indiana University School...TerminatedPost-ERCP PancreatitisUnited States
-
Hospital San PaoloUnknownPost-ERCP PancreatitisItaly
-
Yonsei UniversityRecruiting
-
Chinese University of Hong KongXijing Hospital; Changhai Hospital; Eastern Hepatobiliary Surgery Hospital; Zhejiang... and other collaboratorsRecruitingPost ERCP PancreatitisChina, Hong Kong, Thailand
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPost-ERCP PancreatitisUnited States, Canada
-
Syed Z. Ali, MDCompleted
-
Yonsei UniversityCompletedPost ERCP PancreatitisKorea, Republic of
-
University Medicine GreifswaldTerminatedPost-ERCP PancreatitisGermany
Clinical Trials on Sucralfate
-
Changhai HospitalEisai China Inc.CompletedChronic Erosive GastritisChina
-
Manchester University NHS Foundation TrustNational Institute for Health Research, United KingdomRecruitingRadiation ProctopathyUnited Kingdom
-
Virginia Commonwealth UniversityMedical University of South Carolina; Ochsner Health SystemWithdrawnDyspepsia | Gastroesophageal Reflux Disease | Non Erosive Reflux DiseaseUnited States
-
Ashley Downs BioscienceUnknownNausea | Vomiting | Diarrhea | Oral MucositisUnited States
-
Maria Sklodowska-Curie National Research Institute...Medical Centre for Postgraduate EducationCompleted
-
National Cheng-Kung University HospitalRecruiting
-
Mayo ClinicCompletedEosinophilic EsophagitisUnited States
-
Juravinski Cancer Centre FoundationCompletedHead and Neck Cancer | MucositisCanada
-
Memorial Sloan Kettering Cancer CenterRecruitingRadiation EsophagitisUnited States
-
Thompson Cancer Survival CenterRecruitingEffects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and EsophagitisLaryngeal Cancer | Esophageal Cancer | Oropharynx Cancer | Oral Cavity Cancer | Mediastinal Cancer | Head and Neck Cancers - Tonsils | Chest Wall Tumor | Radiation MucositisUnited States